BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Rigel Pharmaceuticals, Inc. 

1180 Veterans Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-624-1100 Fax: 650-624-1101


View Clinical Trials from BioPharm Insight

Rigel's. Rigel's mission is to become a source of novel, small-molecule drugs to address large, unmet medical needs. We have initiated four development programs: asthma/allergy, hepatitis C, rheumatoid arthritis and oncology. Our first two product candidates, R112 for allergic rhinitis and R803 for hepatitis C, are in clinical testing. We expect to begin a clinical trial of R406 for the treatment of rheumatoid arthritis by the end of 2004, to be followed by initiation of clinical trials with additional product candidates for indications in oncology and asthma. Our approach to drug discovery is based on advanced, proprietary techniques that allow us to identify targets with a demonstrable role in a disease pathway and to screen efficiently for those targets that are likely to be amenable to drug modulation. We believe that this approach to drug discovery will enable us to commence clinical trials with one to two lead compounds each year. Our research efforts are focused in the areas of immunology/inflammation, virology and oncology.

Last Updated: 10-18-04

 Key Statistics

Ownership: Public

Web Site: Rigel Pharmaceuticals, Inc.
Employees: 135
Symbol: RIGL


Drug Discovery

 Company News
Rigel Pharmaceuticals, Inc. (RIGL) Announces Participation At Two Investor Conferences 2/27/2014 6:53:13 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL) Announces Participation At Two Investor Conferences 2/6/2014 6:33:41 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL) Will Present Clinical Product Portfolio Update At J.P. Morgan Healthcare Conference 1/10/2014 6:30:08 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL) To Present At Oppenheimer Healthcare Conference 12/5/2013 6:25:27 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL) Announces Third Quarter 2013 Financial Results 11/5/2013 6:53:02 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL)'s Skin Drug Misses Primary Endpoint, Study Discontinued 10/24/2013 6:55:09 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL) to Present at Stifel Healthcare Conference 9/6/2013 6:28:58 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL) Axes 18 Pct of Workforce, Ends Some Drug Programs 9/5/2013 8:07:18 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL) Shares Fall After Asthma Drug Fails to Meet Phase 2 Goals; Stock Falls -13.50% at Market Close (August 26, 2013) 8/26/2013 6:52:26 AM    More...
Rigel Pharmaceuticals, Inc. (RIGL) Announces Second Quarter 2013 Financial Results 8/6/2013 7:10:24 AM    More...